GREY:IMVIQ - Post by User
Post by
Hideawayon Dec 28, 2020 2:54pm
278 Views
Post# 32188232
Another Missed Deadline
Another Missed DeadlineThis NR does contain encouraging details but, regrettably,they have failed to meet the expectations to commence a phase1/2 trial for COVID-19.The following excerpt from the release is suggesting that the failure is because of "the evolution of the regulatory landscape "
In consideration of the evolution of the regulatory landscape with first vaccines approved and a recent update to Health Canada guidance, as well as the emergence of SARS-CoV-2 variants in different countries, the Company is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in Q1 2021 on its revised clinical plan."
Granted,the situation has changed but they were to slow with progress and there will be more vaccines approved before IMV gets started,if ever.
Our future was and is with cancer treatments,but it is still disappointing to have yet another timeline missed.